These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38066860)

  • 41. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
    Levitz D; Saunthararajah Y; Fedorov K; Shapiro LC; Mantzaris I; Shastri A; Kornblum N; Sica RA; Shah N; Konopleva M; Gritsman K; Braunschweig I; Cooper DL; Pradhan K; Verma A; Feldman EJ; Goldfinger M
    Clin Cancer Res; 2023 Aug; 29(15):2774-2780. PubMed ID: 37341641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
    Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center.
    Freeman T; Williams K; Puto M; Waller A; McLaughlin EM; Blachly JS; Roddy J
    World J Oncol; 2023 Feb; 14(1):40-50. PubMed ID: 36896000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
    Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
    Maiti A; Konopleva MY
    Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
    Gershon A; Ma E; Xu T; Montez M; Naqvi K; Ku G; Cheng WW; Flahavan EM; Kota V; Greenwald DR
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e222-e231. PubMed ID: 36925388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax.
    Hara R; Machida S; Hashimoto N; Ogiya D; Kawai H; Kawakami S; Shiraiwa S; Onizuka M; Ogawa Y; Kawada H; Ando K
    Int J Hematol; 2023 Dec; 118(6):711-717. PubMed ID: 37728705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
    Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.
    Inguva A; Pollyea DA
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):805-811. PubMed ID: 34389272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
    Wang N; He J; Liu F
    Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.
    Neuendorff NR; Gagelmann N; Singhal S; Meckstroth S; Thibaud V; Zhao Y; Mir N; Shih YY; Amaro DMC; Roy M; Lombardo J; Gjærde LK; Loh KP
    J Geriatr Oncol; 2023 Apr; 14(3):101406. PubMed ID: 36435726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia.
    Lachowiez CA; Atluri H; DiNardo CD
    Ther Adv Hematol; 2022; 13():20406207221093964. PubMed ID: 35510212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients.
    Zong L; Yin M; Kong J; Zhang J; Song B; Zhu J; Xue S; Wu X; Wu D; Bao X; Qiu H
    Mol Carcinog; 2023 Oct; 62(10):1572-1584. PubMed ID: 37555764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
    Kwag D; Cho BS; Bang SY; Lee JH; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
    Blood Cancer J; 2022 Dec; 12(12):169. PubMed ID: 36529771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.